Review of category A bioweapons with cutaneous features: Epidemiology, clinical presentation, and contemporary management strategies

被引:0
作者
Osborne, Sara [1 ]
Kam, Olivia [2 ]
Thacker, Shivani [3 ]
Wescott, Raquel [4 ]
Vo, Carolynne [5 ]
Wu, Jashin J. [6 ]
Rojek, Nathan W. [7 ]
Norton, Scott A. [8 ,9 ]
机构
[1] Univ Minnesota, Twin Cities Sch Med, Minneapolis, MN USA
[2] Stony Brook Sch Med, Stony Brook, NY USA
[3] KPC Hemet Med Ctr, Hemet, CA USA
[4] Univ Nevada, Reno Sch Med, Reno, NV USA
[5] Univ Calif Riverside, Riverside Sch Med, Riverside, CA USA
[6] Univ Miami, Miller Sch Med, Miami, FL USA
[7] Univ Calif Irvine, Dept Dermatol, 118 Med Surge 1, Irvine, CA 92697 USA
[8] Uniformed Serv Univ Hlth Sci, Dept Dermatol, Bethesda, MD USA
[9] Uniformed Serv Univ Hlth Sci, Dept Prevent Med, Bethesda, MD USA
关键词
anthrax; bioterrorism; bioweapons; category A; plague; public health; smallpox; tularemia; viral hemorrhagic; ANTIMICROBIAL TREATMENT; TULAREMIA; ANTHRAX; INFECTION; PLAGUE; RECOGNITION; DISEASE;
D O I
10.1016/j.jaad.2025.01.081
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Major health organizations recognize various pathogens as potential bioweapons. Category A bioweapons (anthrax, plague, smallpox, tularemia, and viral hemorrhagic fevers) are the highest priority due to their ease of spread and high mortality rates. As these conditions have cutaneous manifestations, dermatologists may have an important role as front-line responders to indolent or bioterrorism threats. Few dermatologists are adequately prepared to approach the diagnosis and management of these conditions if encountered. Furthermore, despite improvements made in identifying, diagnosing, and treating these conditions over the past 10 years, there persists an absence of a synthesized distribution of these updates customized to adequately equip dermatologists. In this paper, we review the epidemiology, transmission, and dermatologic signs and symptoms of the category A bioweapons listed above. We also offer an overview of the evidence-based strategies for diagnosis and management and provide access to each states' guidelines for reporting these conditions. ( J Am Acad Dermatol 2025;93:165-75.)
引用
收藏
页码:165 / 175
页数:11
相关论文
共 84 条
[1]  
American Public Health Association, 2006, Control of Communicable Diseases Manual, V18th
[2]  
[Anonymous], 2018, FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy
[3]  
[Anonymous], 2018, Emergency Preparedness and Response, Facts About Nitrogen Mustards
[4]  
[Anonymous], 2020, Types of anthrax
[5]  
[Anonymous], 2019, Ebola (Ebola Virus Disease): 2014-2016 Ebola Outbreak in West Africa
[6]  
[Anonymous], 2022, 2019 Table 1
[7]   Selection of Bacillus anthracis isolates resistant to antibiotics [J].
Athamna, A ;
Athamna, M ;
Abu-Rashed, N ;
Medlej, B ;
Bast, DJ ;
Rubinstein, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) :424-428
[8]  
Auwaerter PG, Mandell, Douglas, and Bennett's principles and practice of infectious diseases, V9th, P227
[9]   Anthrax: Where Margins are Merging between Emerging Threats and Bioterrorism [J].
Banerjee, Dibyendu ;
Chakraborty, Baishali ;
Chakraborty, Banya .
INDIAN JOURNAL OF DERMATOLOGY, 2017, 62 (05) :456-458
[10]  
Barel M, 2019, Defense against biological attacks, P239, DOI [10.1007/978-3-030-03071-1_10, DOI 10.1007/978-3-030-03071-1_10]